hetal patel

ImmunoOncology, ophthalmology, clinical drug development, lifelong learner

[CenterForBiosimilars @BiosimCenter]

The FDA has approved Steqeyma (ustekinumab-stba), Celltrion's biosimilar candidate referencing Stelara, for the treatment of psoriatic conditions and IBD.

The approval represents the seventh biosimilar approval for a Stelara competitor.
https://t.co/SFia9a6ZhQ

[CenterForBiosimilars @BiosimCenter]

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps.
https://t.co/OXd7CP5ZQ5

[CenterForBiosimilars @BiosimCenter]

In 2 randomized controlled trials of maintenance therapy for IBD, the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to placebo in patients with Crohn disease and ulcerative colitis.
https://t.co/xu3UmaallU

[hetal patel @patelhs1]

@MaiaKayalMD @LouisVuitton @pedsIBDdoc Love the tag line and right on point:)

[Celltrion @Celltrioninc]

Thank you to everyone who visited our booth at #DDW2024!
It was a pleasure to take part in this year’s congress, share our commitment to accelerating care options for patients with inflammatory bowel diseases and connect with you all. 😄
#DigestiveDiseaseWeek #Gastroenterology #crohnsdisease #ulcerativecolitis #IBD

[Celltrion @Celltrioninc]

Celltrion will be at #DDW2024 – connect with us to learn more about our commitment to the #IBD community.
See you in Washington, D.C.!
#DigestiveDiseaseWeek #Gastroenterology #crohnsdisease #ulcerativecolitis

[Beatriz Gros @Bealoquebea]

Someone reached out suggesting I compile a summary of #IBD H2H trials

His suggestion motivated me to complete the one I had

🌟So, here it is over 35 trials. Hope it proves helpful!
https://t.co/f5mibHsfQn
You'll have to access the website to view it in full.

Happy to add any that I could have missed.

(post-op trials and those with 5ASA/thiopurines will be in a separate document)

[hetal patel @patelhs1]

@Bealoquebea @fgomollon @sepdigestiva @AshkanRA @DCharabaty @ibdseb @Y_ECCO_IBD @ign76 @gveitia @geteccu @JosephHabibi_MD This is amazing and such a great resource @Bealoquebea thank you

[Celltrion @Celltrioninc]

Join us at our #ECCO2024 satellite symposium, ‘Achieving Endoscopic Healing in IBD with Subcutaneous Infliximab: A Path to Improving Long-term Outcomes’. The session focuses on the up-to-date clinical data on biologic treatment in #inflammatoryboweldisease.
#Biosimilars #IBD

[CenterForBiosimilars @BiosimCenter]

Plaque psoriasis problems? A new study shows promising results for CT-P43, a potential biosimilar to the drug Stelara.
Want to know more? Click the link below:
https://t.co/GOpnMgIUqP

[hetal patel @patelhs1]

#CCCongress24
First conference of 2024, and what a good one to start with.
with some great sessions like IBD A to Z, medical management of IBD… to meeting and learning from some of the greatest in the field, presenting posters,to networking.. and also having a little fun. Thank

[Celltrion @Celltrioninc]

Supporting #IBD patients begins with understanding the burden and impact of the disease.
Recognizing this #CCAwarenessWeek, Hetal Patel, Pharmd MBA, Director of Medical Science Liaison at Celltrion USA shares Celltrion USA’s commitment to support people living with IBD.

[SAIA @saia_gi]

Join the conversation & raise #awareness during Crohn's & Colitis Awareness Week (Dec 1-7)!

Let's break the silence, share stories, & support those battling #IBD. Together, we can make a difference! 💜

#IBDawareness #CCAwarenessWeek #StrongerTogether

[Celltrion @Celltrioninc]

This November, #CelltrionHealthcare welcomed #gastroenterologists from 11 countries, discussing emerging trends of inflammatory bowel disease and sharing best practices and knowledge in the #IBD field.
We hope it has been a memorable moment to all.😊
#Gastroenterology

[hetal patel @patelhs1]

Meeting global medical affairs team -Canada and Brazil, learning from world experts, and networking at #acr23 in San Diego was the highlight of the conference.
#celltrionmedicalaffairs #globalmedicalaffairs

[Celltrion @Celltrioninc]

This #WorldScienceDay, we want to recognize this year’s theme: “Building trust in science”.
#CelltrionHealthcare celebrates the power and importance of #science for communities we serve. Stay tuned for updates as we embark on this journey of scientific exploration and innovation.

[Crohn's & Colitis Foundation @CrohnsColitisFn]

The FDA approved Celltrion USA’s ZYMFENTRA® (infliximab-dyyb), the first and only subcutaneous infliximab injection, for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. To learn more visit our IBD Medication Guide: https://t.co/yNLNvZrScA

[hetal patel @patelhs1]

Exciting news from the Celltrion Medical Affairs team at #ACG2023 in Vancouver! On the day of the #Zymfentra (Infliximab subcutaneous drug) approval, we had the opportunity to connect and learn from GI physicians and experts from around the world. It was truly a great experience!

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

Subcutaneous Infliximab approved by FDA. Another good option for our IBD patients.
https://t.co/FEMfv0eHgt

[hetal patel @patelhs1]

@IBD_Afzali @AmCollegeGastro @IssakaMD @DarwinConwell @DrR_Williams @DMGrayMD Congratulations